Sino Biological LDLR Recombinant Human Protein, His Tag

5ug

This recombinant human protein is expressed from a DNA sequence encoding the extracellular domain of human LDLR precursor (NP_000518.1), residues 1 to 788, fused to a polyhistidine tag at the C-terminus

Low density lipoprotein receptor (LDLR) recombinant human protein is supplied as a lyophilized powder. This protein is suitable for use in protein studies such as protein structure analysis and protein-protein interactions. In general, recombinant proteins can also be used as an immunogen, as a protein standard, or in cell biology research applications.Background: Low-density lipoprotein (LDL) is one of the five major groups of lipoprotein that transports cholesterol and triglycerides from the liver to peripheral tissues, and enables fats and cholesterol to move within the water-based solution of the blood stream. The Low-Density Lipoprotein Receptor (LDLR) is the prototype member of the LDLR family of scavenger receptors which is involved in receptor-mediated endocytosis of specific ligands. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. LDLR recognizes the apoprotein B100 which is embedded in the phospholipid outer layer of LDL particles, as well as the apoE protein found in chylomicron remnants and VLDL remnants (IDL). After taken into the cell ending up in lysosomes, LDL is degraded and the cholesterol is made available for repression of microsomal enzyme HMG CoA reductase, the rate-limiting step in cholesterol synthesis. As a mosaic protein, the extracellular region of LDLR consists of seven N-terminal complement-like cysteinerich repeats followed by three EGF like repeats with a β-propeller YWTD containing motif, and a membrane proximal Ser/Thr rich region. Furthermore, it is reported that in case of HIV-1 infection, LDLR functions as a receptor for extracellular Tat (HIV-1 transactivator) into neurons, mediating its internalization in uninfected cells. Mutations in LDLR gene cause the autosomal dominant disorder, familial hypercholesterolemia.

N-terminal Sequence Analysis: Ala 22

Activity: Measure by its ability to bind to human PCSK9 in a functional ELISA: 1. Immobilized human PCSK9 at 10µg/mL (100µL/well) has been shown to bind biotinylated recombinant human LDLR, the ED50 of biotinylated human LDLR is 0.61µg/mL; 2. Immobilized mouse PCSK9 at 10µg/mL (100µL/well) has been shown to bind biotinylated recombinant human LDLR, the ED50 of biotinylated human LDLR is 0.12µg/mL

Related Products

Product Content Feedback

The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.

Product Title

Full Name:

Email Address:*

User Name:

Telephone Number:

What type of issue did you experience with the content on the page?*

Please provide a detailed description of the issue or request*

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our
Privacy Policy.